Short interest for Exelixis gives investors a sense of the degree to which investors are betting on the decline of Exelixis's stock. Short interest data is updated every two weeks.

Exelixis Stock (NASDAQ:EXEL), Short Interest Report

Exelixis

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Long Ideas

News

Small Cap

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

BYON

EXEL

WTBA

Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.

Around $4M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying

Bristol_Myers_Squibb,_Moreton,_Wirral_-_IMG_0369

Biotech

Large Cap

Health Care

General

Bristol Myers Squibb &amp; Exelixis Inc revealed four-year follow-up results from CheckMate -9ER trial.

Bristol Myers, Exelixis Reveal 4-Year Follow-Up Results From Cancer Treatment Study

Media

BROS

GOLD

PAGP

PARA

RYAAY

UNFI

On CNBC’s &#34;Mad Money Lightning Round,&#34; Jim Cramer said  Franco-Nevada Corporation  (NYSE: FNV) is a &#34;great diversified 

Jim Cramer Likes This &#39;Well-Run&#39; Airline, Says This Entertainment Stock Has &#39;Balance Sheet From Hell&#39;

Exelixis Inc

Exela Technologies Inc

Exela Technologies, Inc. - 6.00% Series B Cumulative Convertible Perpetual Preferred Stock

Exelon Corp

Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Exelixis, revealing an average target of $26.4, a high estimate of $28.00, and a low estimate of $25.00. This upward trend is evident, with the current average reflecting a 6.67% increase from the previous average price target of $24.75.
<img src="https://www.benzinga.com/files/images/story/2024/1714586466_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of Exelixis by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yaron Werber</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$27.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Peter Lawson</td>
<td>Barclays</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$27.00</td>
<td>-</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Stephen Willey</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$25.00</td>
<td>$23.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Exelixis. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Exelixis compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Exelixis's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Exelixis's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EXEL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Exelixis analyst ratings.</a>
<h2>About Exelixis</h2>
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
<h3>Exelixis's Financial Performance</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Exelixis showcased positive performance, achieving a revenue growth rate of 13.15% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 17.83%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 3.71%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Exelixis's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 2.89%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.08.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

The Analyst Verdict: Exelixis In The Eyes Of 5 Experts

TD Cowen analyst Yaron Werber maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Buy and raises the price target from $25 to $27.

Price Target

TD Cowen Maintains Buy on Exelixis, Raises Price Target to $27

WIIM

Exelixis shares are trading lower after the company reported worse-than-expected Q1 financial results.

Guidance

Exelixis Maintains FY24 Financial Guidance, Total Revenues Of $1.825B-$1.925B, Est $1.909B

Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) reported quarterly earnings of $0.17 per share which missed the analyst consensus estimate of $0.24 by 29.17 percent. This is a 6.25 percent increase over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $425.226 million which missed the analyst consensus estimate of $460.621 million by 7.68 percent. This is a 4.02 percent increase over sales of $408.788 million the same period last year.

Earnings

Earnings Misses

Exelixis Q1 2024 Adj EPS $0.17 Misses $0.24 Estimate, Sales $425.226M Miss $460.621M Estimate

Exelixis shares are trading lower after Barclays downgraded the stock from Overweight to Equal-Weight.

Barclays analyst Peter Lawson downgrades Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) from Overweight to Equal-Weight and maintains the price target from $25 to $25.

Downgrades

Barclays Downgrades Exelixis to Equal-Weight, Maintains Price Target to $25

In the preceding three months, 4 analysts have released ratings for Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>), presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $26.25, with a high estimate of $28.00 and a low estimate of $25.00. This current average has increased by 7.89% from the previous average price target of $24.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1712768431_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Exelixis among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$27.00</td>
<td>-</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Stephen Willey</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$25.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Peter Lawson</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$24.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Exelixis. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Exelixis compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Exelixis's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Exelixis's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EXEL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Exelixis analyst ratings.</a>
<h2>Unveiling the Story Behind Exelixis</h2>
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
<h3>Exelixis: A Financial Overview</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Exelixis displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 13.15%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Exelixis's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 17.83%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Exelixis's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 3.71%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 2.89%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Exelixis's debt-to-equity ratio is below the industry average. With a ratio of 0.08, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Exelixis Stock

JMP Securities analyst Silvan Tuerkcan reiterates Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Market Outperform and maintains $27 price target.

Reiteration

JMP Securities Reiterates Market Outperform on Exelixis, Maintains $27 Price Target

Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company&#39;s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
Below is a look at a few recent notable insider purchases. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.
<h3>Beyond </h3>
<ul>
<li>The Trade: Beyond, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/byon#NYSE">BYON</a>) Executive Chairman Marcus Lemonis <a href="https://www.benzinga.com/quote/BX/analyst-ratings"> acquired a total of 3,650 shares </a> an average price of $27.17. To acquire these shares, it cost around $99,171.</li>
<li>What&rsquo;s Happening: Beyond posted a wider-than-expected fourth-quarter loss on Feb. 20.</li>
<li>What Beyond Does: Beyond Inc is an online retailer that provides products and services through websites. The company offers a broad range of products, including furniture, d&eacute;cor, area rugs, bedding and bath, home improvement, outdoor, and kitchen and dining items, BMMG (like books, magazines, CDs), electronics, and other items.</li>
</ul>
<h3>West Bancorporation </h3>
<ul>
<li>The Trade: West Bancorporation, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wtba#NASDAQ">WTBA</a>) CEO and President David D Nelson acquired a total of 2,007 shares at an average price of $17.55. To acquire these shares, it cost around $35,223.</li>
<li>What&rsquo;s Happening: On Jan. 25, West Bancorp posted downbeat quarterly results.</li>
<li>What West Bancorporation Does: West Bancorp Inc is a United States-based company that offers a full range of deposit services, including checking, savings, and money market accounts and time certificates of deposit.</li>
</ul>
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a> 
<h3>Hudson Pacific Properties </h3>
<ul>
<li>The Trade: Hudson Pacific Properties, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hpp#NYSE">HPP</a>) Director Barry A Sholem <a href="https://www.benzinga.com/sec/insider-trades/"> bought a total of 80,000 shares </a> at an average price of $6.69. To acquire these shares, it cost around $535,200.</li>
<li>What&rsquo;s Happening: On Feb. 12, Hudson Pacific Properties reported worse-than-expected fourth-quarter financial results.</li>
<li>What Hudson Pacific Properties Does: Hudson Pacific Properties Inc is a real estate investment trust that acquires, operates, and owns office buildings and media and entertainment properties, such as sound stages, on America&#39;s West Coast.</li>
</ul>
<h3>Exelixis </h3>
<ul>
<li>The Trade: Exelixis, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/exel#NASDAQ">EXEL</a>) Director Caligan Partners LP Johnson <a href="https://www.benzinga.com/sec/insider-trades/"> bought a total of 190,000 shares </a> at an average price of $20.70. The insider spent around $3.93 million to buy those shares.</li>
<li>What&rsquo;s Happening: On Feb. 6, Exelixis posted upbeat quarterly earnings.</li>
<li>What Exelixis Does: Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer.</li>
</ul>
&nbsp;
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/02/37279701/investor-optimism-improves-further-s-p-500-settles-at-record-high"> Investor Optimism Improves Further; S&amp;P 500 Settles At Record High </a>

RBC Capital analyst Gregory Renza maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Outperform and raises the price target from $26 to $28.

RBC Capital Maintains Outperform on Exelixis, Raises Price Target to $28

Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) reported its Q4 earnings results on Tuesday, February 6, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Exelixis beat estimated earnings by 50.0%, reporting an EPS of $0.33 versus an estimate of $0.22.
Revenue was up $55.73 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company missed on EPS by $0.05 which was followed by a 4.23% drop in the share price the next day.
Here's a look at Exelixis's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.15</td>
<td>0.22</td>
<td>0.15</td>
<td>-0.12</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.10</td>
<td>0.31</td>
<td>0.16</td>
<td>-0.03</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>472.21M</td>
<td>450.07M</td>
<td>424.10M</td>
<td>417.50M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>471.92M</td>
<td>469.85M</td>
<td>408.79M</td>
<td>423.92M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Exelixis <a href="https://www.benzinga.com/quote/EXEL/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: Exelixis Q4 Earnings

Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) reported quarterly earnings of $0.33 per share which beat the analyst consensus estimate of $0.22 by 50 percent. This is a 1200 percent increase over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $479.65 million which missed the analyst consensus estimate of $484.88 million by 1.08 percent. This is a 13.15 percent increase over sales of $423.92 million the same period last year.

Exelixis Q4 Adj EPS $0.33 Beats $0.22 Estimate, Sales $479.65M Miss $484.88M Estimate

AEIS

AGCO

AMCR

AMGN

AMRK

AOSL

ARCB

ARMK

ARWR

ASTL

ATEN

ATHM

AUDC

AVNW

AZEK

AZPN

CARR

CEIX

CHKP

CINF

CRNC

CRUS

CTSH

DCPH

DIOD

ENPH

FRSH

FTNT

GAIN

GEHC

GILD

HIMX

HLNE

ICHR

INGR

INNV

INSP

INTA

JKHY

KREF

KTCC

LPTV

LSAK

LUMN

MODN

MRCY

MSGS

MSTR

PLUS

QGEN

Earnings Scheduled For February 6, 2024

Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-02-06. Here's what investors need to know before the announcement.
Analysts estimate that Exelixis will report an earnings per share (EPS) of $0.22. 
Exelixis bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company missed EPS by $0.05, which was followed by a 4.23% drop in the share price the next day.
Here's a look at Exelixis's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.15</td>
<td>0.22</td>
<td>0.15</td>
<td>-0.12</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.10</td>
<td>0.31</td>
<td>0.16</td>
<td>-0.03</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.23%</td>
<td>3.62%</td>
<td>0.78%</td>
<td>2.72%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1707159661_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Exelixis were trading at $21.49 as of February 02. Over the last 52-week period, shares are up 24.15%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/EXEL/earnings">To track all earnings releases for Exelixis visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For Exelixis

Stifel analyst Stephen Willey maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Hold and raises the price target from $23 to $25.

Stifel Maintains Hold on Exelixis, Raises Price Target to $25

Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $26.57, with a high estimate of $31.00 and a low estimate of $23.00. This current average has increased by 15.52% from the previous average price target of $23.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1706619647_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive Exelixis is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peter Lawson</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Kaveri Pohlman</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$27.00</td>
<td>-</td>
</tr>
<tr>
<td>David Lebowitz</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$31.00</td>
<td>-</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$27.00</td>
<td>-</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$26.00</td>
<td>-</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$27.00</td>
<td>-</td>
</tr>
<tr>
<td>Jefferson Harralson</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$23.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Exelixis. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Exelixis compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Exelixis's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EXEL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Exelixis analyst ratings.</a>
<h2>Delving into Exelixis's Background</h2>
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
<h3>Understanding the Numbers: Exelixis's Finances</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Exelixis's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2023, the company achieved a revenue growth rate of approximately 14.62%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Exelixis's net margin is impressive, surpassing industry averages. With a net margin of 0.22%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Exelixis's ROE stands out, surpassing industry averages. With an impressive ROE of 0.04%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Exelixis's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.03% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Exelixis's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.08.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Exelixis: 7 Analysts Share Their Views

Barclays analyst Peter Lawson maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Overweight and raises the price target from $24 to $25.

Barclays Maintains Overweight on Exelixis, Raises Price Target to $25

– Cabozantinib in combination with atezolizumab reduced the risk of disease progression or death by 35% in patients with metastatic castration-resistant prostate cancer –
– Findings to be presented during an oral presentation at ASCO GU 2024 –
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.exelixis.com%2F&amp;esheet=53887477&amp;newsitemid=20240124801283&amp;lan=en-US&amp;anchor=Exelixis%2C+Inc.&amp;index=1&amp;md5=c859223171be1cfa6de1cc756e2064d6">Exelixis, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) today announced detailed results from CONTACT-02, a phase 3 pivotal study evaluating cabozantinib (CABOMETYX&#xAE;) in combination with atezolizumab compared with a second novel hormonal therapy (NHT) in patients with metastatic castration-resistant prostate cancer (mCRPC) and measurable extra-pelvic soft tissue disease who have progressed on one prior NHT. The detailed findings are being presented during Oral Abstract Session A: Prostate Cancer at 7:55 a.m. PST on January 25 at the American Society of Clinical Oncology 2024 Genitourinary Cancers Symposium (ASCO GU).
"Patients with metastatic castration-resistant prostate cancer with prior progression on a novel hormone therapy and who have measurable soft tissue metastasis experience the worst outcomes among advanced prostate cancer patients and have limited treatment options," said Neeraj Agarwal, M.D., FASCO, Senior Director for Clinical Research at Huntsman Cancer Institute at the University of Utah and the global lead investigator of the trial. "CONTACT-02 is the only phase 3 study evaluating a tyrosine kinase inhibitor and an immune checkpoint inhibitor to show a statistically significant improvement in progression-free survival and a trend for overall survival in these patients. I am encouraged by these results and the potential for cabozantinib plus atezolizumab to be a widely available treatment option for our patients."
As <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.exelixis.com%2Fnews-releases%2Fnews-release-details%2Fexelixis-and-ipsen-announce-positive-results-phase-3-contact-02&amp;esheet=53887477&amp;newsitemid=20240124801283&amp;lan=en-US&amp;anchor=announced&amp;index=2&amp;md5=ccb0ba3d88a12d686111ccd38e74067b">announced</a> in August 2023, CONTACT-02 met one of its primary endpoints, demonstrating a statistically significant improvement in progression-free survival (PFS) as assessed by a blinded independent radiology committee (BIRC) and per RECIST 1.1. The PFS analysis was conducted in the first 400 randomized patients in the intent-to-treat (PFS ITT) population and per protocol. Similar results were observed for all patients.
Detailed results presented at ASCO GU show that at a median follow-up of 14.3 months for the PFS ITT population, the hazard ratio (HR) was 0.65 (95% confidence interval [CI]: 0.50-0.84; p=0.0007); the median PFS (mPFS) was 6.3 months for cabozantinib in combination with atezolizumab compared with 4.2 months for second NHT. This was nearly identical to the PFS for the ITT population (n=507): HR was 0.64 (95% CI: 0.50-0.81, p=0.0002); mPFS was 6.3 months for cabozantinib in combination with atezolizumab and was 4.2 months for second NHT. At a median follow-up of 12.0 months for the ITT population, the median overall survival (OS) was 16.7 months for cabozantinib in combination with atezolizumab compared with 14.6 months for second NHT (HR: 0.79; 95% CI: 0.58-1.07; p=0.13). While a trend toward OS improvement was observed, the data were immature and did not meet the threshold for statistical significance. The study will continue to the next analysis of OS, anticipated in 2024.
The PFS benefit and the trend for an OS benefit were observed across subgroups of high-risk populations, as presented in Table 1.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="2">TABLE 1</td>
<td colspan="2" rowspan="1">Liver metastasis</td>
<td colspan="2" rowspan="1">Prior docetaxel for mCSPC</td>
<td colspan="2" rowspan="1">Bone metastasis</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;Cabozantinib + atezolizumab</td>
<td colspan="1" rowspan="1">&nbsp;Second NHT</td>
<td colspan="1" rowspan="1">&nbsp;Cabozantinib + atezolizumab</td>
<td colspan="1" rowspan="1">&nbsp;Second NHT</td>
<td colspan="1" rowspan="1">&nbsp;Cabozantinib + atezolizumab</td>
<td colspan="1" rowspan="1">&nbsp;Second NHT</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Median PFS &nbsp;per BIRC, months (95% CI)</td>
<td colspan="1" rowspan="1">6.2 (4.0-9.1)</td>
<td colspan="1" rowspan="1">2.1 (2.0-2.3)</td>
<td colspan="1" rowspan="1">8.8 (6.2-9.2)</td>
<td colspan="1" rowspan="1">4.1 (2.3-4.3)</td>
<td colspan="1" rowspan="1">6.3 (6.0-8.8)</td>
<td colspan="1" rowspan="1">4.1 (2.8-5.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Patients, n</td>
<td colspan="1" rowspan="1">51</td>
<td colspan="1" rowspan="1">48</td>
<td colspan="1" rowspan="1">45</td>
<td colspan="1" rowspan="1">44</td>
<td colspan="1" rowspan="1">162</td>
<td colspan="1" rowspan="1">155</td>
</tr>
<tr>
<td colspan="1" rowspan="1">PFS HR (95% CI)</td>
<td colspan="2" rowspan="1">0.43 (0.27-0.68)</td>
<td colspan="2" rowspan="1">0.57 (0.34-0.97)</td>
<td colspan="2" rowspan="1">0.67 (0.50-0.88)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Median OS, months (95% CI)</td>
<td colspan="1" rowspan="1">16.4 (8.3-NE)</td>
<td colspan="1" rowspan="1">9.8 (5.5-11.3)</td>
<td colspan="1" rowspan="1">20.9 (10.1-NE)</td>
<td colspan="1" rowspan="1">11.3 (9.0-NE)</td>
<td colspan="1" rowspan="1">16.4 (11.4-18.8)</td>
<td colspan="1" rowspan="1">11.4 (10.4-14.6)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Patients, n</td>
<td colspan="1" rowspan="1">59</td>
<td colspan="1" rowspan="1">60</td>
<td colspan="1" rowspan="1">57</td>
<td colspan="1" rowspan="1">58</td>
<td colspan="1" rowspan="1">206</td>
<td colspan="1" rowspan="1">196</td>
</tr>
<tr>
<td colspan="1" rowspan="1">OS HR (95% CI)</td>
<td colspan="2" rowspan="1">0.60 (0.35-1.02)</td>
<td colspan="2" rowspan="1">0.56 (0.29-1.08)</td>
<td colspan="2" rowspan="1">0.74 (0.54-1.02)</td>
</tr>
<tr>
<td colspan="7" rowspan="1">BIRC = blinded independent radiology committee; CI = confidence interval; HR = hazard ratio; mCSPC = metastatic castration-sensitive prostate cancer; NE = not evaluable; NHT = novel hormone therapy; OS = overall survival; PFS = progression-free survival</td>
</tr>
</tbody>
</table>
</figure>
Treatment-emergent adverse events (AEs) occurred in 97% of patients treated with cabozantinib in combination with atezolizumab (n=248) compared with 87% of patients treated with a second NHT (n=253), 48% and 23% of which were grade 3/4, respectively. Grade 5 treatment-emergent AEs occurred in 8% of patients treated with the combination regimen compared with 12% of patients treated with a second NHT; no grade 5 treatment-related AEs occurred in either arm. Treatment-related AEs led to the discontinuation of any treatment component in 13% of patients treated with the combination regimen and 2% of patients treated with a second NHT. For all treatment components, the treatment-related AEs leading to discontinuation were 5% vs. 2%, respectively.
"Given there are limited options after progression on novel hormonal therapy, we recognize the need for a regimen that can delay disease progression, that has an acceptable tolerability profile and that is widely available to patients who may not have the means or desire to travel to specialized centers for other therapies," said Amy Peterson, M.D., Executive Vice President, Product Development &amp; Medical Affairs, and Chief Medical Officer, Exelixis. "Our decision to conduct CONTACT-02, based upon a signal we observed in COMET-01, underscores our commitment to patients with advanced prostate cancer and to improving their standard of care. We look forward to discussing these important results with the U.S. Food and Drug Administration, and to learning more in the next analysis of overall survival, anticipated this year."
About CONTACT-02
CONTACT-02 is a global, multicenter, randomized, phase 3, open-label study that randomized 507 patients 1:1 to the experimental arm of cabozantinib in combination with atezolizumab and the control arm of a second NHT (either abiraterone and prednisone or enzalutamide). The two primary endpoints of the trial are PFS and OS. The study included patients with mCRPC who have measurable extra-pelvic soft tissue metastasis and who have progressed on one prior NHT. The secondary endpoint is objective response rate per BIRC. The trial is sponsored by Exelixis and co-funded by Ipsen, Roche and Takeda Pharmaceutical Company Limited (Takeda). Takeda is conducting the trial in Japan. More information about CONTACT-02 is available at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04446117&amp;esheet=53887477&amp;newsitemid=20240124801283&amp;lan=en-US&amp;anchor=ClinicalTrials.gov&amp;index=3&amp;md5=27f9652891dc026371ea61cc73dca12d">ClinicalTrials.gov</a>.

Exelixis Announces Detailed Results Of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib In Combination With Atezolizumab In Metastatic Castration-Resistant Prostate Cancer Presented At ASCO GU 2024

Exelixis, Inc. (EXEL) Q1 2024 Earnings Call Transcript

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Incyte (INCY – Research Report) and Exelixis (EXEL...

Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Exelixis (EXEL)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Legend Biotech (LEGN – Research Report), Organon (...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Legend Biotech (LEGN), Organon (OGN) and Exelixis (EXEL)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Exelixis (EXEL – Research Report), Cyclo Therapeutic...

Analysts Are Bullish on These Healthcare Stocks: Exelixis (EXEL), Cyclo Therapeutics (CYTH)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eli Lilly & Co (LLY – Research Report), Exelixis (EX...

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Exelixis (EXEL) and Zynex (ZYXI)

Bank of America Securities analyst Jason Gerberry maintained a Buy rating on Exelixis (EXEL – Research Report) today. The company's shares closed y...

Exelixis (EXEL) Receives a Buy from Bank of America Securities

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Inari Medical (NARI – Research Report), Exelixis (EXEL – Research...

Analysts Offer Insights on Healthcare Companies: Inari Medical (NARI), Exelixis (EXEL) and Merit Medical Systems (MMSI)

Andrew Berens, an analyst from Leerink Partners, maintained the Hold rating on Exelixis (EXEL – Research Report). The associated price target is $1...

Hold Rating on Exelixis: Analyzing Q1 Revenue Shortfalls and Pipeline Progress

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Exelixis (EXEL – Research Report), Atricure (ATRC – ...

Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Atricure (ATRC) and Glaukos (GKOS)

Exelixis: With Patent Litigation Decision Due Soon, There Are Options

ATRC

CYTH

GKOS

INCY

IPSEY

LEGN

MMSI

NARI

TEVA

XOMA

ZYXI

Press Releases

European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets

Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024

Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February

Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update

Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March

Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024

Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Exelixis Stock (NASDAQ:EXEL), Short Interest Report

People Also Watch